Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of temsirolimus plus nelfinavir in advanced cancer
NL-OMON33441Phase 1Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of temsirolimus and nelfinavir in Nonhematologic neoplasms and cancer, sponsored by Amsterdam University Medical Center. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Planned start Mar 2009; status: not yet recruiting.
02
Drugs
temsirolimusnelfinavir
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON33441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33441.